Requiring Certain Manufacturers To Report Drug Pricing Information for Part B ( 414.802 and 414.902) In the CY 2022 PFS final rule, it was stated that the new provisions finalized in that rule at 414.802 and 414.804 implemented new statutory requirements under sections 1847A and 1927 of the Act, as amended by section 401 of Division CC, Title IV of the CAA, 2021 (for the purposes of this section of this proposed rule, hereinafter is referred to as section 401), which requires manufacturers without a Medicaid National Drug Rebate Agreement (NDRA) to report ASP information to CMS for calendar quarters beginning on January 1, 2022, for drugs or biologicals payable under Medicare Part B and described in sections 1842(o)(1)(C), (E), or (G) or 1881(b)(14)(B) of the Act, including items, services, supplies, and products that are payable under Part B as a drug or biological (86 FR 65560)
Together, they create a synergistic effect that accelerates healing, improves flexibility, and reduces recovery time from injuries
Larazotide's barrier-restoration effect addresses the bidirectional gut-oral microbiome relationship strengthening the mucosal defense layer that systemic inflammation and periodontal disease progressively erode
It summarises areas of ongoing research and does not constitute medical advice, product claims, or recommendations for human use.
